Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875250 | 0.99 | KMT2A (0.41) | KMT2AMEN1POLBGRIN2BALDH1A1 | |
| SCHEMBL4868476 | 0.90 | GRIN2B (0.40) | KMT2AMEN1GRIN2BALDH1A1GAA | |
| SCHEMBL4877153 | 0.89 | GRIN2B (0.40) | GRIN2BMAPTRAB9A | |
| SCHEMBL4877305 | 0.89 | GRIN2B (0.43) | KMT2AGRIN2BALDH1A1GAAHPGD | |
| SCHEMBL4875238 | 0.88 | ALDH1A1 (0.39) | KMT2AMEN1POLBGRIN2BALDH1A1 | |
| SCHEMBL4876718 | 0.88 | ALDH1A1 (0.39) | KMT2AMEN1POLBGRIN2BALDH1A1 | |
| SCHEMBL4877137 | 0.88 | CBX7 (0.39) | POLBGRIN2BGAATSHRMAPT | |
| SCHEMBL4876223 | 0.88 | GRIN2B (0.39) | KMT2AMEN1GRIN2BALDH1A1GAA | |
| SCHEMBL3934917 | 0.87 | GRIN2B (0.38) | KMT2AMEN1GRIN2BALDH1A1GAA | |
| SCHEMBL4868740 | 0.87 | GRIN2B (0.41) | KMT2AMEN1GRIN2BALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | KMT2A 4254/4885MEN1 4834/4885POLB 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.